首页 | 本学科首页   官方微博 | 高级检索  
     


Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
Authors:Ann S. LaCasce  R. Gregory Bociek  Ahmed Sawas  Paolo Caimi  Edward Agura  Jeffrey Matous  Stephen M. Ansell  Howland E. Crosswell  Miguel Islas-Ohlmayer  Caroline Behler  Eric Cheung  Andres Forero-Torres  Julie Vose  Owen A. O’Connor  Neil Josephson  Yinghui Wang  Ranjana Advani
Affiliation:1. Dana-Farber Cancer Institute, Boston, MA, USA;2. University of Nebraska Medical Center, Omaha, NE, USA;3. Columbia University Medical Center, New York, NY, USA;4. University Hospitals Seidman Cancer Center, Cleveland, OH, USA;5. Charles A. Sammons Cancer Center, Dallas, TX, USA;6. Colorado Blood Cancer Institute, Denver, CO, USA;7. Mayo Clinic, Rochester, MN, USA;8. St. Francis Hospital, Greenville, SC, USA;9. The Jewish Hospital-Mercy Health, Cincinnati, OH, USA;10. Pacific Hematology Oncology Associates, San Francisco, CA, USA;11. The Oncology Institute of Hope & Innovation, Whittier, CA, USA;12. University of Alabama at Birmingham, Birmingham, AL, USA;13. Seattle Genetics, Inc, Bothell, WA, USA;14. Stanford Cancer Institute, Stanford, CA, USA
Abstract:
Keywords:Hodgkin lymphoma  first salvage therapy  autologous stem cell transplantation  brentuximab vedotin  bendamustine
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号